Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › TGF(β)-MIR200-MIG6 pathway and its use in the treatment of cancer as an indicator of resistance to EGFR inhibitors

TGF(β)-MIR200-MIG6 pathway and its use in the treatment of cancer as an indicator of resistance to EGFR inhibitors

US Patent 10801071 · Granted Oct 13, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treati2025
Pharmaceutical agents targeting cancer stem cells2021
Prophylactic protection against viral infections, particularly HIV2020
Hypermethylation biomarkers associated with poor survival outcomes for head and 2019
Method to use viral and host methylation markers for cervical cancer screening a2019
Dual sequence-capture method for quantifying trans renal HPV DNA in urine2017
Hypermethylation biomarkers for detection of head and neck squamous cell cancer2016
Hypermethylation biomarkers for detection of cervical cancer2014
Global DNA hypomethylation and biomarkers for clinical indications in cancer2014
Neoplasia screening compositions and methods of use2013
Methods for the diagnosis and treatment of lung cancer2011
BRAF mutation T1796A in thyroid cancers2011